← Back to Screener
Avita Medical, Inc. Common Stock (RCEL)
Price$5.00
Favorite Metrics
Price vs S&P 500 (26W)-8.75%
Price vs S&P 500 (4W)20.63%
Market Capitalization$157.45M
All Metrics
Book Value / Share (Quarterly)$0.17
P/TBV (Annual)7.22x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)27.66%
Cash Flow / Share (Quarterly)$-1.07
Price vs S&P 500 (YTD)44.85%
Gross Margin (TTM)83.27%
Net Profit Margin (TTM)-67.85%
EPS (TTM)$-1.75
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$-1.75
Revenue Growth (5Y)19.63%
EPS (Annual)$-1.74
ROI (Annual)-132.31%
Gross Margin (Annual)83.26%
Net Profit Margin (5Y Avg)-83.10%
Cash / Share (Quarterly)$0.59
Revenue Growth QoQ (YoY)-4.30%
ROA (Last FY)-86.16%
Revenue Growth TTM (YoY)11.45%
EBITD / Share (TTM)$-1.48
ROE (5Y Avg)-303.00%
Operating Margin (TTM)-59.40%
Cash Flow / Share (Annual)$-1.07
P/B Ratio35.00x
P/B Ratio (Quarterly)74.59x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.66x
Net Interest Coverage (TTM)-8.71x
ROA (TTM)-78.43%
EPS Incl Extra (Annual)$-1.74
Current Ratio (Annual)0.57x
Quick Ratio (Quarterly)0.44x
3-Month Avg Trading Volume0.23M
52-Week Price Return-43.02%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.44
P/S Ratio (Annual)2.20x
Asset Turnover (Annual)1.27x
52-Week High$10.29
Operating Margin (5Y Avg)-83.16%
EPS Excl Extra (Annual)$-1.74
CapEx CAGR (5Y)6.99%
26-Week Price Return0.00%
Quick Ratio (Annual)0.44x
13-Week Price Return46.02%
Total Debt / Equity (Annual)9.39x
Current Ratio (Quarterly)0.57x
Enterprise Value$190.188
Revenue / Share Growth (5Y)14.79%
Asset Turnover (TTM)1.16x
Book Value / Share Growth (5Y)-44.92%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.69x
Pretax Margin (Annual)-67.83%
Cash / Share (Annual)$0.59
3-Month Return Std Dev82.79%
Gross Margin (5Y Avg)85.00%
Net Income / Employee (TTM)$-0
ROE (Last FY)-1374.64%
Net Interest Coverage (Annual)-8.71x
EPS Basic Excl Extra (Annual)$-1.74
Receivables Turnover (TTM)6.86x
Total Debt / Equity (Quarterly)9.39x
EPS Incl Extra (TTM)$-1.75
Receivables Turnover (Annual)6.86x
ROI (TTM)-102.95%
P/S Ratio (TTM)2.20x
Pretax Margin (5Y Avg)-83.00%
Revenue / Share (Annual)$2.57
Tangible BV / Share (Annual)$1.89
Price vs S&P 500 (52W)-78.11%
Year-to-Date Return48.99%
5-Day Price Return4.68%
EPS Normalized (Annual)$-1.74
ROA (5Y Avg)-47.00%
Net Profit Margin (Annual)-67.85%
Month-to-Date Return38.92%
Cash Flow / Share (TTM)$-1.31
EBITD / Share (Annual)$-1.48
Operating Margin (Annual)-59.40%
LT Debt / Equity (Annual)9.39x
ROI (5Y Avg)-48.07%
LT Debt / Equity (Quarterly)9.39x
EPS Basic Excl Extra (TTM)$-1.75
P/TBV (Quarterly)24.15x
P/B Ratio (Annual)74.59x
Inventory Turnover (TTM)1.69x
Pretax Margin (TTM)-67.84%
Book Value / Share (Annual)$0.17
Price vs S&P 500 (13W)43.16%
Beta2.05x
Revenue / Share (TTM)$2.36
ROE (TTM)-337.90%
52-Week Low$3.22
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
RCELAvita Medical, Inc. Common Stock | 2.20x | 19.63% | 83.27% | -59.40% | $5.00 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Avita is a medical device company focused on the RECELL system, a proprietary burn treatment technology that creates Spray-on Skin from small patient samples in approximately 30 minutes, reducing the need for traditional skin grafts. The FDA-approved system is used across most of the nation's 140 burn centers and has expanded indications for soft-tissue reconstruction. While holding approvals in multiple countries, Avita focuses primarily on the US market, though international sales—particularly in Japan—are growing.